Abstract. Small cell lung cancer is a major cause of mortality worldwide. microRNAs (miRNAs) are involved in various biological processes through regulating gene expression. In the present study, to identify the miRNAs involved in human small cell lung cancer at the genome-wide level, Solexa sequencing was employed to sequence two small RNA (sRNA) libraries from small cell lung cancer tissues (LC sRNA library) and the corresponding normal tissues (NT sRNA library). Deep sequencing of the two sRNA libraries identified a number of conserved miRNAs and differential expression analysis of these miRNAs revealed 81 miRNAs differentially expressed in small cell lung cancer, of which more than half were downregulated. The expression trends determined by sequencing were validated by reverse transcription-quantitative polymerase chain reaction analysis. The annotations for the targets of these miRNAs were predicted. This study provides valuable information for understanding the regulatory mechanisms of miRNAs involved in human small cell lung cancer.
Introduction
MicroRNAs (miRNAs) are small non-coding RNA molecules, ~22 nucleotides long, which are widely distributed in plants and animals (1, 2) . The primary miRNA transcripts are cleaved by Drosha and Dicer enzymes to form mature miRNAs, which serve as posttranscriptional negative gene regulators by either cleaving mRNA or inhibiting translation (3, 4) . Through such mechanisms, miRNAs are involved in various biological processes, including organ development, tissue differentiation, cell cycle regulation and cancer development (4) (5) (6) .
Lung cancer is the predominant cause of cancer-related mortality worldwide and its pathogenesis is closely associated with tobacco smoking. Lung cancer is categorized into two main histological groups: Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Regulation of miRNAs is closely associated with tumor initiation, promotion and progression (7) . Recently, increasing evidence has demonstrated that miRNAs may be associated with lung cancer. A previous study revealed that an increase in hsa-miR-196a expression levels was a characteristic molecular change in NSCLC (8, 9) , and that hsa-miRNA-196a promoted NSCLC cell proliferation and invasion via targeting HOXA5 (10) . Overexpression of miR-200 was shown to reduce the expression levels of NSCLC prognostic biomarkers in H1299 and BEAS-2B cells (11) . miR-449a, which inhibited migration and invasion through targeting c-Met, was found to be downregulated in NSCLC tissues and cell lines (12) . Reduced expression of miR-101 was associated with overexpression of EZH2 and exhibited tumor-suppressive functions in NSCLC (13) . This evidence suggests that miRNAs are crucial in NSCLC; however, little is known regarding the functions and regulation of miRNAs in SCLC.
In the present study, Solexa sequencing was used to generate a large quantity of small RNA (sRNA) data for SCLC and corresponding normal tissues. Sequence analysis was employed to identify specific miRNAs associated with SCLC and these miRNAs were validated by reverse transcriptionquantitative polymerase chain reaction (RT-qPCR).
Materials and methods
Samples and total RNA isolation. The experimental specimens were obtained with informed consent between 2011 and 2012 from six patients at similar stages of SCLC. The SCLC tissues and corresponding normal tissues from healthy subjects were collected at the time of surgery and prior to chemotherapy at the Second Affiliated Hospital of Harbin Medical University (Harbin, China). This study was approved by the Hospitals' Ethical Review Committee. The isolated SCLC and corresponding normal tissues were harvested in liquid nitrogen and stored at -80˚C. The total RNA was extracted from the SCLC tissues and controls using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA).
sRNA library construction. Two sRNA libraries were constructed from the SCLC tissues (LC sRNA library) and the corresponding normal tissues (NT sRNA library) using methods described previously (14) . Briefly, total RNA was purified by electrophoretic separation on a 15% Tris/Borate/EDTA urea denaturing PAGE gel (Sangon Biotech Co., Ltd., Shanghai, China) and sRNA molecules in the range of 15-30 nucleotides (ligated to adapters at the end of 5' and 3' sRNAs using T4 RNA ligase) were enriched (Takara Biotechnology Co., Ltd., Dalian, China). The adapter-ligated sRNAs were subsequently transcribed to complementary DNA (cDNA) by Super-Script II Reverse Transcriptase (Invitrogen Life Technologies) and then amplified by PCR. The PCR products were purified and recovered, then subjected to deep sequencing using an Illumina-Solexa 1G Genetic Analyzer (Illumina, Inc., San Diego, CA, USA) at the Beijing Genomics Institute (Shenzhen, China).
Differential expression analysis of miRNAs involved in SCLC.
The raw readings generated by deep sequencing were analyzed through bioinformatics. These sequences were mapped to the human genome using the short oligonucleotide alignment program (15) with a perfect match. Sequences matching ribosomal (r)RNAs, small cytoplasmic (sc)RNAs, small nucleolar (sno)RNAs, snRNAs and transfer (t)RNAs in the NCBI GenBank (http://www.ncbi.nih.gov/GenBank/) database and Rfam (http://rfam.sanger.ac.uk/) database were discarded. The conserved miRNAs were predicted by aligning to miRBase 20.0 (http://www.mirbase.org/index.shtml); then the 187 conserved miRNAs (data not shown) were annotated by matching with miRBase 20.0. TargetScan (http://www. targetscan.org) was used for annotation of the targets of conserved miRNAs.
Differential expression levels of miRNAs were analyzed as determined by the sequence readings of LC and NT sRNA libraries. The abundance of miRNAs was normalized to one million (normalized expression = actual miRNA count/total count of clean readings x 1,000,000). The ratio between the two sRNA libraries was calculated as follows: Ratio = miRNA normalized readings in LC library/miRNA normalized readings in NT library. The P-values were calculated according to the equation in Fig. 1 . When the ratio was >1.5-fold or <0.67-fold, and P<0.05, the miRNAs were considered to be up-or downregulated respectively in SCLC.
Validation of differential expression levels of miRNAs by RT-qPCR. sRNAs (<200 nt) were isolated from the SCLC tissues (LC sRNA library) and the normal tissues using a mirVana miRNA Isolation kit (Ambion, Carlsbad, CA, USA). The tissues used for validation were the same as tissues used for the deep sequencing. The sRNAs were polyadenylated by poly(A) polymerase using the Poly(A) Tailing kit (Ambion) and then cDNA was synthesized with a Quant reverse kit (Tiangen, Beijing, China) (15) . RT-qPCR was performed using an ABI 7500 Fast Real-time PCR machine (Applied Biosystems, Foster City, CA, USA) using an SYBR Premix Ex TaqTM kit (Takara Bio, Inc., Shiga, Japan) in a 20-µl reaction volume, containing 2 µl diluted cDNA, 200 nM of each primer and 1X PCR Master mix. The amplification conditions were provided by Takara Bio Inc.. The expression levels of miRNAs were normalized to those of the U6 sRNA. Three replicates were analyzed for each sample. The primers for the validated miRNAs are shown in Table I .
Statistical analysis.
The correlation analysis between the miRNA expression profile was conducted using bivariate correlation in SPSS software (SPSS, Inc., Chicago, IL, USA). P-values were used to reflect the significance of miRNA differential expression between these two sRNA libraries. P<0.05 indicated a statistically significant difference.
Results

Analysis of sRNAs.
To identify the responsive miRNAs in the SCLC patients, two sRNA libraries were constructed from the SCLC tissues (LC sRNA library) and the normal tissues (NT sRNA library), generating 25.1 million (LC) and 24.6 million (NT) raw readings. These sRNAs were classified into five categories: rRNAetc (rRNA, scRNA, snoRNA, snRNA and tRNA), known miRNAs (miRNAs in miRBase 20.0), exon, intron and unknown sRNA (Fig. 2) . The results revealed that the proportion of total known miRNA readings decreased from 31.96% (NT) to 28.63% (LC) in response to SCLC, suggesting that the known miRNAs may be important in SCLC. However, the percentage of total rRNAetc readings increased from 23.87% (NT) to 26.86% (LC), implying that rRNAetc may exert certain functions in SCLC. Little difference was identified in the percentages of introns and unknown sRNAs between SCLC and normal tissue.
Identification of miRNAs in SCLC.
Those miRNAs with a ratio of >1.5-fold or <0.67-fold between the two libraries, and P<0.05 (Table II) , were regarded as differentially expressed miRNAs in SCLC. A total of 81 differentially expressed Figure 1 . Equation for the P-value for the differential expression of the normal tissue (NT) and small cell lung cancer tissue (LC) micro (mi)RNAs. N1, total number of readings in the NT short RNA library; N2, total number of readings in the LC short RNA library, x, number of readings for an miRNA in the control library; y, number of readings for an miRNA in the LC sRNA library miRNAs were identified. The abundance of these miRNAs varied between 4 and 4,343 readings. Of these, 18 corresponding miRNA*s were identified, including hsa-miR-29a-3p and hsa-miR-29a-5p, and hsa-miR-30a-3p and hsa-miR-30a-5p (miRNA* is another mRNA that derives from the same hairpin structure as that of the original miRNA, and is complementary to the original miRNA). Notably, the expression levels of these 18 miRNAs were found to be associated with the corresponding miRNA*s, which exhibited similar expression patterns. For example, hsa-miR-146a-3p was downregulated and hsa-miR146a-5p was also downregulated, implying that the expression of miRNA*s followed the corresponding miRNAs. A total of 34 miRNAs were upregulated in SCLC and the remainder were downregulated. The most notable changes occurred in hsa-miR520c-3p, which had the greatest reduction in expression levels in SCLC with a ratio of 0.12 (LC/NT), and hsa-miR-148b-3p, which exhibited the greatest increase with 7.39-fold more readings sequenced in LC than in NT. These marked alterations Table I . Primers used for reverse transcription-polymerase chain reaction analysis.
Reverse primer GCGAGCACAGAATTAATACGAC U6 small RNA GCAGGGGCCATGCTAATCTTCTCTGTATCG a V=A, G, C; N=A, T, G, C. Table II . Differentially expressed miRNAs in small cell lung cancer.
miRNA readings
Normalized readings Table II . Continued. in expression levels, suggest that miRNAs are crucial in the response to SCLC.
miRNA readings Normalized readings ----------------------------------------------------------------------------------
RT-qPCR validation.
To validate the expression levels of the miRNAs involved in SCLC, RT-qPCR was performed on 36 miRNA sequences from the SCLC tissues and the corresponding normal tissues (Fig. 3) . Of these 36 miRNAs, 6 miRNAs and the corresponding miRNA*s were identified, including hsa-miR-29a-3p and hsa-miR-29a-5p, and hsa-miR30a-3p and hsa-miR-30a-5p ( Fig. 2A) . This indicates that the mature miRNA and corresponding miRNA* exhibit similar expression patterns and are important in SCLC. The results revealed similar abundance profiles with Solexa sequencing and RT-qPCR analysis; they indicated that hsa-miR-21-5p was upregulated in the SCLC tissues. However, a few differences regarding the ratio (LC/NT) between RT-qPCR and Solexa sequencing were identified; for example, the ratio of hsa-miR-224-3p was 4.24 with sequencing data, but the RT-qPCR ratio was only 3.64, possibly since different data normalization protocols of the two methods were provided. The sequencing was normalized to the whole abundance of all miRNAs sequenced by Solexa, while the RT-qPCR was normalized to the expression levels of U6 sRNA.
Annotation of the targets of miRNAs involved in SCLC.
The targets of the miRNAs involved in SCLC were annotated by the TargetScan database. The functions of the targets of these miRNAs were involved in organ development, tissue differentiation, cell apoptosis and defense, signal transduction and the electron transfer chain. For example, the target of hsa-miR-29 encodes vascular endothelial growth factor A, which has various effects, including mediating increased vascular Glutamate receptor, metabotropic 5, coiled-coil domain containing 67, fucosyltransferase 9 (α (1,3) fucosyltransferase), H3 histone, family 3B hsa-miR- 24 Calcitonin receptor, mannose-P-dolichol utilization defect 1, kinase suppressor of ras 2, CKLF-like MARVEL transmembrane domain containing 4, spermatogenesis associated, serine-rich 2-like has-miR-25 CD69 molecule, folliculin interacting protein 1, actin, α, cardiac muscle 1; F-box and WD repeat domain containing 7; aspartate β-hydroxylase hsa-miR-29 PIK3R1, Vascular endothelial growth factor A, PIK3RZ hsa-miR- 30 MAPKS, NRG3, KRAS, PIK3CD, RARB, KRAS, CCNEZ, ITGA6, peroxisome proliferator-activated receptor γ, coactivator 1β, makorin ring finger protein 3 hsa-miR-34
Cyclin E, p53; hyperpolarization activated cyclic nucleotide-gated potassium channel 3, family with sequence similarity 76, member A; neuron navigator 3 hsa-miR-96
Leucine-rich repeats and calponin homology domain containing 2; adenylate kinase 3; spindlin 1; dihydrolipoamide S-acetyltransferase hsa-miR-99 THAP domain containing, apoptosis associated protein 2; kelch repeat and BTB (POZ) domain containing 8; ependymin related protein 1 (zebrafish) hsa-miR-101 transportin 1; family with sequence similarity 108, member C1; family with sequence similarity 108, member C1; FLJ20160 protein hsa-miR-103 Dicer 1, ribonuclease type III; forkhead box P1; HIV-1 Rev binding protein; eukaryotic translation initiation factor 5; armadillo repeat containing 1 hsa-miR-106
Carnitine O-octanoyltransferase; zinc finger with KRAB and SCAN domains 1; RAB22A, member RAS oncogene family; cytochrome b reductase 1 hsa-miR-125
StAR-related lipid transfer domain containing 13; zinc finger protein 792; SH3 domain and tetratricopeptide repeats 2; zinc finger and SCAN domain containing 29 hsa-miR-126 ITGA6, CRK, SPRED1; epidermal growth factor-like domain 7; protein tyrosine phosphatase, non-receptor type 9; low density lipoprotein receptor-related protein 6; F-box protein 33 hsa-miR-139 TATA element modulatory factor 1; USP6 N-terminal like; T-box 1; early B-cell factor 1; protein prenyltransferase α subunit repeat containing 1; S phase cyclin A-associated protein in the ER hsa-miR-141
Transmembrane protein 170B; zinc finger E-box binding homeobox 2; RAN binding protein 6; zinc finger RNA binding protein; protein kinase, cAMP-dependent, catalytic, β hsa-miR-143
Solute carrier family 30 (zinc transporter), member 8; vasohibin 1; homeodomain interacting protein kinase 2; development and differentiation enhancing factor-like 1 hsa-miR-145
Epidermal growth factor receptor, IGF-1R; family with sequence similarity 108, member C1; SLIT-ROBO Rho GTPase activating protein 2; ATP-binding cassette, sub-family E (OABP), member 1; tripartite motif-containing 2 hsa-miR-146
Zinc finger protein 826; TNF receptor-associated factor 6; zinc finger and BTB domain containing 2; neuro-oncological ventral antigen 1; chemokine binding protein 2 hsa-miR-148/152 Cholecystokinin B receptor; ATPase, H + transporting, lysosomal accessory protein 2; oxysterol binding protein-like 11; chloride channel 6 hsa-miR-182
Regulator of G-protein signaling 17; microphthalmia-associated transcription factor; ARP2 actin-related protein 2 homolog (yeast); microfibrillar-associated protein 3; neurocalcin delta hsa-miR-183 VIL2-coding-protein Ezrin; A kinase anchor protein (gravin) 12; phosphatidylinositol glycan anchor biosynthesis, class X; neurotrophic tyrosine kinase, receptor, type 2; profilin 2; SLAIN motif family, member 1 hsa-miR-192 IKAROS family zinc finger 2 (Helios); IKAROS family zinc finger 2 (Helios); poly(A) binding protein, cytoplasmic 4 (inducible form); dihydrolipoamide branched chain transacylase E2 hsa-miR-205 RAB11 family interacting protein 1 (class I); RAB11 family interacting protein 1 (class I); cell division cycle 2-like 6 (CDK8-like); AP2 associated kinase 1; lysophosphatidylcholine acyltransferase 1 permeability, vasculogenesis and endothelial cell growth, promoting cell migration and inhibiting apoptosis (17, 18) . The target of hsa-miR-375 encodes phosphoinositide-dependent kinase-1, which is important in the signaling pathways activated by several growth factors and hormones, including insulin (19) . F-box and WD repeat domain-containing 7 encoded by hsa-miR-223 may regulate intestinal cell lineage commitment (20) . The various functions of these targets implied that these responsive miRNAs exert crucial regulatory functions in SCLC. However, no functional annotations were identified for certain miRNAs, including hsa-miR-185 and hsa-miR-224 (Table III) .
Discussion
SCLC is a leading cause of cancer-related morality worldwide. There are numerous reports regarding the roles of miRNAs in NSCLC (10, 12, 21, 22) , however, little is known regarding the regulatory functions of miRNAs in SCLC.
In the present study two sRNA libraries were constructed from SCLC and normal tissues. Sequence analysis and RT-qPCR validation identified 81 miRNAs differentially expressed in SCLC. This may provide useful information for improving the diagnosis, prevention and treatment of this disease. Notably, the expression levels of miRNA*s were associated with the corresponding miRNAs and revealed similar expression patterns. This may be due to miRNAs and the corresponding miRNA*s being derived from the same precursor (23) . In addition, more than half the miRNAs associated with SCLC were downregulated and the total readings of known miRNAs were reduced (Fig. 2) , implying that the corresponding targets become activated and trigger defense mechanisms against illness. However, further studies are required to characterize the miRNAs involved in SCLC.
Only a few studies have been published regarding the miRNAs involved in SCLC. Miko et al (24) employed microarray and RT-qPCR analyses to determine the miRNA expression profile in primary SCLC, and the result revealed that at least 24 miRNAs were differentially expressed between the normal lung and primary SCLC tumor tissues. A previous study performed gene expression profiling of drug-resistant SCLC cells by combining miRNA and cDNA expression analyses, and identified 61 significantly differentially expressed miRNAs (25) . However, in the present study, a relatively complete analysis of miRNAs involved in SCLC at a genome-wide level was performed and certain miRNAs were reported to be involved in SCLC for the first time, including hsa-miR451. In addition, there were a few differences in the results of these studies. For example, hsa-miR-223 was downregulated in the previous study (25) while upregulated in the present study in SCLC tissues; this may be due to different methods for profiling miRNAs. The functions of the targets of miRNAs involved in SCLC were diverse and revealed inhibitory roles in the regulation of the corresponding targets. In the present study, the expression levels of hsa-miR-34-c, hsa-miR-126 and hsa-miR-145 were downregulated, while the expression levels of hsa-miR-183 was upregulated (Table II) . The targets of hsa-miR-34, cyclin E and p53, are associated with the cell cycle and tumor formation (26, 27) ; the low expression of hsa-miR-34 may result in upregulation of cyclin E and p53, which is crucial in the development of SCLC. The epidermal growth factor receptor (EGFR) encoded by the target of hsa-miR-145 may inhibit cancer growth (28) ; the downregulation of hsa-miR-145 in SCLC may generate an increase in the expression levels of EGFR and thus promote cancer growth. The targets of hsa-miR-126 encode epidermal growth factor-like domain 7 (EGFL7), which is involved in cellular responses, such as cell migration and blood vessel formation (29) . The downregulation of hsa-miR-126 may activate EGFL7 and advance tumor growth in vivo. The VIL2-coding-protein Ezrin, a known target of hsa-miR-183 is involved in migration and invasion (30) ; overexpression of hsa-miR-183 may repress VIL2-coding-protein Ezrin and inhibit migration and invasion of lung cancer cells, perhaps since defense mechanisms against illness have been initiated. Therefore, the evidence suggests that these identified miRNAs are important in SCLC.
In conclusion, 81 miRNAs involved in SCLC have been identified via deep sequencing and the profiles for a subset of miRNAs were validated by RT-qPCR. The functions for the target genes of these miRNAs were analyzed. These findings contribute to the understanding of the function of posttranscriptional regulation of miRNA in SCLC development and progression, which is essential for improving the diagnosis, prevention and treatment of this disease.
